Home・Aandelen Lijst・Vericel Corp

Vericel Corp

Open

SectorGezondheidszorg

43.99 -1.1

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.27

Max

44.91

Belangrijke statistieken
By Trading Economics
Inkomsten	13M 6.3M
Verkoop	9M 77M
K/W Sectorgemiddelde	93.511 57.002
EPS	0.04
Winstmarge	8.136
Werknemers	398
EBITDA	8.5M 5.6M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+38.08% upside

Dividenden
By Acuity
Volgende Winsten	5 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-64M 2.3B
Vorige openingsprijs	45.09
Vorige sluitingsprijs	43.99

Nieuwssentiment

By Acuity

100%

325 / 340 Rangschikking in Healthcare

Vericel Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 aug 2026, 19:43 UTC

Vericel Corp shares are lower today, reflecting ongoing weakness below the 20-day moving average and near the lower end of their one-month range.

11 aug 2026, 19:46 UTC

News

Vericel Corp shares are higher as analysts maintain a "Moderate Buy" consensus, with HC Wainwright's target at $70 and Truist raising its target to $58.

10 aug 2026, 19:46 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting a broader market decline and volatility amid uncertainty over the Federal Reserve's interest rate policy.

7 aug 2026, 19:16 UTC

Correlated Moves

Vericel Corp's shares rise, supported by gains in the ARK Genomic Revolution ETF and Russell 2000 Index, despite earlier fluctuations in trading.

6 aug 2026, 19:26 UTC

Correlated Moves

Vericel Corp shares declined during Thursday's session, tracking broader market trends. The stock remains near the lower end of its one-month trading range.

5 aug 2026, 19:26 UTC

Correlated Moves

Vericel Corp shares are lower today, reflecting broader market trends as the Russell 2000 Index declines. The stock remains below its 20-day moving average.

3 aug 2026, 20:03 UTC

Correlated Moves

Vericel Corp shares are advancing, supported by significant gains in the broader market and major tech stocks, contributing to positive investor sentiment.

31 jul 2026, 20:02 UTC

Correlated Moves

Vericel Corp's price is lower today, influenced by declines in the Biotechnology sub-sector and a falling Russell 2000 Index.

30 jul 2026, 20:36 UTC

Correlated Moves

Vericel Corp shares gained in after-market trading, aligning with a rising Russell 2000 Index. The stock remains above its 20-day moving average.

29 jul 2026, 19:27 UTC

Correlated Moves

Vericel Corp shares declined during Wednesday's session, continuing a downward trend since Tuesday's close, amid broader market weakness reflected in the Russell 2000 Index.

28 jul 2026, 21:02 UTC

Vericel Corp shares are lower in after-market trading, reflecting broader market caution amid declines in the Nikkei 225 Index and technology sector concerns.

27 jul 2026, 20:31 UTC

Vericel Corp shares declined during after-market hours amid unusual selling pressure. The stock remains below its 20-day moving average with no specific news identified.

24 jul 2026, 19:46 UTC

Correlated Moves

Vericel Corp reported first-quarter revenue of $39.2 million, missing estimates. Shares are lower amid broader market declines affecting small-cap biotechnology stocks.

22 jul 2026, 20:13 UTC

Vericel Corp shares are trading higher in after-market hours, influenced by broader market volatility amid rising crude oil prices and geopolitical tensions.

21 jul 2026, 14:31 UTC

Vericel Corp shares are higher, supported by overall market momentum and a recovery in Asian markets, particularly the Nikkei 225 Index.

20 jul 2026, 17:46 UTC

Correlated Moves

Vericel Corp shares are lower today, aligning with a decline in the ARK Genomic Revolution ETF and the Russell 2000 Index.

Peer Vergelijking

Prijswijziging

Vericel Corp Prognose

Koersdoel

By TipRanks

38.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 61.5 USD 38.08%

Hoogste 72 USD

Laagste 58 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vericel Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Vericel Corp - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Vericel Corp

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.